The kinetics of the immune response to the 23-valent pneumococcal polysaccharide vaccine (PPV) were studied in 38 children who received bone marrow transplants (BMTs). Antipneumococcal antibody concentrations increased 1 and 3 months after vaccination for all 5 serotypes tested, but, in 21 children, the vaccine was not adequately immunogenic. Children vaccinated !18 months after receiving a BMT had a 4.2-fold increased odds of poor response ( ). Antibody concentrations returned close to baseline levels 9 months after vacci-P p .06 nation. Avidity declined significantly as early as 1 month after vaccination and remained low thereafter. Antibody concentration responses to PPV were superior among 9 healthy control children ( ); 37 of 38 children with a BMT elicited adequate, persistent immune re-P p .001 sponses to Haemophilus influenzae conjugate vaccine. Immune responses to PPV in children with a BMT are suboptimal, short lived, and associated with declining avidity. The different kinetics of antibody concentration and avidity indicate that both markers should be used for evaluating pneumococcal vaccines in this high-risk population.
consideration for the evaluation of immune responses to vaccination [5, 6] . However, there are no data on the avidity of PPV antibody responses in child recipients of BMTs.
To thoroughly evaluate pneumococcal vaccination in children with BMTs, we studied the kinetics of concentration, isotype pattern, and avidity of PPV immune responses in such subjects up to 12 months after vaccination. For comparison, we also evaluated the immune responses to Haemophilus influenzae-tetanus conjugate polysaccharide vaccine (PRP-T) in the same children, to study differences between thymus-dependent and -independent responses in this setting.
Subjects and Methods

Study population.
Thirty-eight children (24 boys) were recruited from the Bone Marrow Transplantation Unit, Aghia Sophia Children's Hospital, Athens. BMT indications included malignancy ( ) , b-thalassemia ( ), severe combined immunodefin p 20 n p 15 ciency ( ), Job's syndrome ( ), and osteopetrosis ( ). n p 1 n p 1 n p 1 BMT was autologous in 10 children and allogeneic in 25; 3 children received grafts from matched, unrelated donors. No children had been vaccinated previously with PPV or PRP-T or had chronic graft-versus-host disease. One child had had a splenectomy. Thirtyfour children were receiving penicillin prophylaxis. We also obtained data on 1-month responses to PPV for 9 healthy control subjects of similar ages. 
Vaccination schedule.
All children received 1 subcutaneous dose of PPV (Pneu-Immune 23; Lederle Laboratories, Pearl River, NY). All BMT recipients were vaccinated subsequently with PRP-T vaccine (ActHib; Pasteur Mérieux, Lyon, France). Blood samples were collected before and 1, 3, 6, 9, and 12 months after vaccination. Serum samples were separated, frozen, and stored (Ϫ20ЊC) until tested.
Antibody concentrations. IgG antibodies for pneumococcal serotypes (PS) 3, 6B, 14, 19F, and 23F were measured by use of a modified ELISA [7] . Absorption of serum antibodies to the common cell wall polysaccharide was accomplished by incubation (30 min at 37ЊC) of the test serum (1:50) with cell wall polysaccharide antigen (10 mg/mL; Statens Seruminstitut, Copenhagen). For determination of IgG1 and IgG2 subclass PS-antibodies specific for 14 and 19F, monoclonal mouse anti-human IgG1 and IgG2 were added (clones HP 6070 and HP 6002, respectively; Zymed Laboratories, San Francisco), followed by alkaline phosphatase-conjugated goat anti-mouse IgG antibody (Jackson Immunoresearch Laboratories, West Grove, PA). Results (in mg/mL) were calculated on the officially assigned values of the 89-SF reference serum (donated by C. Frash, Food and Drug Administration, Bethesda). Polyribosylribitol phosphate (PRP) IgG and subclasses were measured by using H. influenzae type b oligosaccharide-human serum albumin conjugate (HBOHA; Wyeth-Lederle Vaccines and Pediatrics, West Henrietta, NY) as capture antigen and Center for Biologics Evaluation and Research (Bethesda, MD) standard lot 1983 as reference serum.
Avidity. Relative antibody avidity was determined by a modified elution ELISA [8] . A serum dilution chosen to give an absorbance of 1.0 was loaded onto microtiter plates coated with 10 mg/mL of polysaccharide or 1 mg/mL HBOHA and left for 2 h at 37ЊC. Ammonium thiocyanate (NH 4 SCN; Sigma, St. Louis), a chaotropic compound that interferes with the antigen-antibody reaction, was added subsequently, in concentrations ranging from 0.25 M to 4 M, and left for 15 min at 37ЊC. Addition of NH 4 SCN does not affect the amount of polysaccharide bound to the plate. The remainder of the assay was done following the pneumococcalor PRP-specific ELISAs. The shift in the binding curve due to NH 4 SCN correlates to antigen-antibody binding strength. The avidity index (AI) corresponds to the NH 4 SCN concentration required to give a 50% reduction in absorbance at 492 nm. The interassay coefficient of variation was 5.5%-12.7% for pneumococcal and 5.5% for PRP ELISAs.
Statistical methods. Comparisons of continuous measures used the Wilcoxon signed rank test and, for paired measurements, the Mann-Whitney U test. An adequate response was defined as a 12- fold rise in antibody concentration. A patient was considered to be a "poor responder" if he or she had an adequate response in !3 of 10 measurements, 1 and 3 months after vaccination (5 PSspecific responses were measured at each of the 2 time points). Univariate and multivariate logistic regressions examined candidate predictors of poor response (age, sex, BMT type, underlying diagnosis, time of vaccination, low IgG2, CD4:CD8 ratio, and CD3 T cell and CD19 B cell counts). Linear regressions evaluated predictors of antibody concentration and avidity changes. Analyses were conducted using SPSS software, version 8.0 (SPSS, Chicago); P values are 2-tailed. Only 6 of the 38 BMT recipients responded to у3 serotypes 1 month after vaccination, compared with 6 of 9 control subjects (risk ratio, 0.24;
Results
PS-specific immune responses.
). The fold-increase in antibody P p .001 concentration at 1 month was more prominent among controls than among BMT recipients for all 5 serotypes (table 1) . Twenty-one children with BMTs were poor responders (!3 adequate PS-specific responses of a total of 10 tested at 1 and 3 months). Furthermore, in children with BMTs, antibody re- sponses were short lived, and average concentrations returned close to baseline 9 months after vaccination ( figure 1A Avidity of PS-specific antibodies. There were modest correlations between the baseline AIs of the 5 serotypes (7/10 correlation coefficients were 10.3, with ). Baseline avidity P ! .10 was unrelated to age, time of vaccination, sex, or immunologic parameters ( for all correlation coefficients). AIs de-P 1 .10 creased significantly after vaccination for all 5 serotypes. Avidity stabilized at the new levels as early as 1 month after vaccination, and there was no statistically significant change for any of the 5 serotypes between 1-and 12-month values ( figure  1B) . No demographic, clinical, or immunologic parameters correlated with avidity changes.
The AIs for PS serotypes 3 and 23F were significantly higher at baseline in controls than in BMT recipients ( and P p .04 , respectively). Among controls, the AIs for 2 of 5 sero-P p .01 types decreased significantly at 1 month (table 1) .
PRP-specific immune responses. All but 6 children achieved titers 11 mg/mL at 1 month; all but 1 achieved such levels at 3 months. Titers were maintained 12 months after vaccination. The fold-increase versus baseline was significantly larger for PRP than for PPV ( for all time points , , , and , respectively), P p .02 P p .03 P ! .001 P p .007 but not for serotype 23F ( ). Knowledge of the baseline P p .54 avidity was generally not predictive of avidity at 12 months.
Baseline IgG concentrations generally did not correlate with baseline avidity. Similarly, IgG concentrations 12 months after vaccination did not correlate with the respective AIs. When all serotypes were considered, a larger decline in avidity correlated modestly with a larger increase in antibody concentration in the same period ( , ). r p Ϫ.22 P p .004
Discussion
This is the first study to document the kinetics of the immune response, including IgG subclasses and avidity, to the 23-valent PPV in children who have received BMTs. Despite a limited sample size, our study suggests that these antibody responses are inadequate in this high-risk population. Criteria of an adequate immune response to PPV have not been clearly defined. Musher et al. [9] considered as responders those subjects who mounted a у2-fold increase in half the tested serotypes. With these criteria, 9% of normal subjects are poor responders. Despite more lenient criteria, most of our patients did not respond. The only other study that has been done in a similar population [2] reported 50% PPV immunogenicity in children vaccinated 1-2 years after receiving a transplant, whereas all children who were vaccinated later responded. This overestimate is probably due to lack of absorption of the nonspecific and, probably, nonprotective cell wall polysaccharide antibodies [10] .
The lapse of time after BMT may predict the response. Seventy-seven percent of children vaccinated !18 months after transplantation were poor responders; however, vaccination after this period induced adequate responses in 56%, which suggests a maturation delay in the response to PPV after BMT [2] . However the IgG2 predominance suggests that this delay does not involve impaired immunoglobulin class switching. Modest associations with other parameters, such as low serum IgG2 or CD4:CD8 ratio, could have been missed because of small sample size.
Increases in antibody concentrations were short lived and disappeared within 6 months. Twelve-month levels could be predicted by the early titers and, on average, they had returned to baseline. Rubins et al. [6] reported that both young and elderly adults maintain high antibody levels for 16 months after immunization. Revaccination is recommended every 3-4 years in adults; however, according to our data, for children who have had BMTs, this period should be much shorter.
In contrast, PRP-T immunogenicity, isotype pattern, and kinetics of antibody concentration were satisfactory and similar to what is known for healthy infants receiving routine PRP-T vaccination. This finding provides further evidence for the improved immunogenicity of conjugate polysaccharide vaccines in subjects unable to respond to polysaccharide antigens.
Avidity measurements offer complementary information. High-avidity pneumococcal antibodies have better opsonizing capacity in vitro and offer better protection to mice [4] . PPV administration resulted in an early and significant decrease in AI, and there was no avidity maturation afterwards, as in the case with PRP-T. To our knowledge, this is the first study to report a detrimental effect in avidity after receipt of PPV. Two other studies [6, 11] reported no significant changes in AI in young and elderly adults after PPV administration. We also observed avidity decreases after PPV was given to 9 healthy children, which suggests a possible age-related phenomenon.
The kinetics of antibody concentration and avidity revealed that 6-12 months after PPV vaccination, antibody levels had returned to baseline, whereas avidity was lower than at baseline. Since antibody avidity may become biologically more impor-tant at low serum antibody concentrations [12] , it is possible that, during that period, children with BMTs are more susceptible to pneumococcal disease.
PPV is recommended for administration at 6 months after BMT to cover the period of highest risk for invasive disease [13] . However, the immune responses generated by PPV in this setting are poor, short lived, and associated with decreased antibody avidity, and children vaccinated so early after BMT are more likely to be poor responders. Although repeated measurements of antibody concentrations and frequent revaccination may be an option, alternative vaccines are urgently needed for children receiving BMTs. Pneumococcal conjugate vaccines have shown improved immunogenicity in subjects unable to respond to PPV [14] and may establish immunologic memory, but no data are available for their immunogenicity in children who have had BMTs. In our study population, immune responses to the conjugate PRP-T vaccine were adequate, long lasting, and associated with avidity maturation. The different kinetics of antibody concentration and avidity between a thymus-dependent and a thymus-independent polysaccharide vaccine among children receiving BMTs, in association with evidence that avidity is a surrogate of the induction of immunologic memory for conjugate vaccines [15] , suggest that both markers should be used in evaluating conjugate pneumococcal vaccines in this setting.
